TB Research

Spirocyclic compounds: potential drug leads in the fight against <i>Mycobacterium tuberculosis</i>

Kumar P, Singampalli A, Bandela R, Srimounika B, Rajyalakshmi SI, Devi A, Nanduri S, Venkata Madhavi Y

Future medicinal chemistry · 2025-03

Abstract

TB drug discovery needs scientists' attention since drug resistance in TB, including extensively drug-resistant TB (XDR-TB) and multidrug-resistant TB (MDR-TB), is a major healthcare concern. Since millions of fatalities from tuberculosis are recorded each year, there is an urgent need to discover new anti-tubercular medications that will either eradicate or control the disease. Spiro compounds have garnered a lot of attention in medicinal chemistry these days because of various biological activities mainly because of their adaptability and structural resemblance to significant pharmacophores. This article overviews the synthesis and activity of spirocyclic compounds as anti-tubercular agents. Both synthesized and naturally occurring spiro chemicals exhibit antitubercular properties. The promising antitubercular potential shown by some of the spirocyclic compounds has attracted scientists to explore them further to develop molecules with improved pharmacodynamic and pharmacokinetic properties and new mechanisms of action with enhanced safety and efficacy in tuberculosis. The current review covers the exploration of spiro compounds from the year 2004 to 2024 for the combat of Tuberculosis. This review gives the comprehensive advancements in this scaffold which would help the logical design of powerful, less toxic, and more effective spirocyclic anti-TB medicinal molecules.

MeSH terms

  • Animals
  • Humans
  • Mycobacterium tuberculosis
  • Tuberculosis
  • Spiro Compounds
  • Antitubercular Agents
  • Molecular Structure
  • Drug Discovery